Primarily, miRNA-371a-3p is known to be mainly overexpressed in SEs, mixed NSTs, and embryonic carcinoma, usually combined with the presence of wild-type p53, and exploiting its oncogenic activity by inhibiting LATS2 (large tumor suppressor kinase 2) [87]. The gene discussed is LATS2; the disease is embryonal carcinoma.